Nov 5, 2021

Featuring perspectives from Drs Ross Camidge, Alexander Drilon and Justin Gainor, including the following topics: 

• Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) with an ALK Rearrangement
• • Introduction (0:00)
  • Case: A woman in her mid 30s with newly diagnosed metastatic NSCLC with an ALK mutation — Nikesh Jasani, MD (5:58)
  • Case: A woman in her early 50s with metastatic adenocarcinoma of the lung with an ALK rearrangement — Lowell L Hart, MD (10:03)
• Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with NSCLC with RET Alterations
• • Case: A woman in her early 60s with metastatic adenocarcinoma of the lung, PD-L1 0%, KIF5B-RET fusion — Mohamed K Mohamed, MD, PhD (15:02)
  • Case: A man in his early 70s with metastatic adenocarcinoma of the lung, PD-L1 65%, KIF5B-RET fusion — Joshua Bauml, MD (18:08)
• Current and Future Directions in the Management of NSCLC with ROS1 Rearrangement
• • Case: A man in his late 60s with metastatic adenosquamous carcinoma of the lung, PD-L1 >95%, ROS1 rearrangement — Margaret Deutsch, MD (25:24)
  • Case: A woman in her late 50s with metastatic adenocarcinoma of the lung with a ROS1 fusion and severe rheumatoid arthritis — Gigi Chen, MD (29:49)
• Rational Approaches to Targeting BRAF in Patients with NSCLC
• • Case: A man in his early 60s with metastatic adenocarcinoma of the lung with a BRAF V600E mutation, PD-L1 TPS 80% — Neil Morganstein, MD (38:04)
  • Case: A man in his early 70s with metastatic NSCLC with a BRAF V600E mutation — KS Kumar, MD (42:59)
• Other Validated Targets Beyond EGFR (eg, MET, KRAS G12C)
• • Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with MET exon 14 skipping and MET amplification mutations, PD-L1 TPS 95% — Dr Mohamed (47:02)
  • Case: A woman in her mid 40s with metastatic adenocarcinoma of the lung with a KRAS G12C mutation — Sulfi Ibrahim, MD (50:57)

CME information and select publications